Albireo Pharma - ALBO Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALBO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALBO, but not buy additional shares or sell existing shares.
View ALBO analyst ratings or view top-rated stocks.

7 brokers have issued twelve-month target prices for Albireo Pharma's shares. Their ALBO share price forecasts range from $42.00 to $59.00. On average, they expect the company's stock price to reach $48.00 in the next twelve months. This suggests a possible upside of 8.7% from the stock's current price.
View analysts price targets for ALBO or view top-rated stocks among Wall Street analysts.

Albireo Pharma's stock was trading at $21.61 at the beginning of the year. Since then, ALBO shares have increased by 104.3% and is now trading at $44.15.
View the best growth stocks for 2023 here.

Albireo Pharma, Inc. (NASDAQ:ALBO) released its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported $2.90 earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $3.28. The biopharmaceutical company earned $3.66 million during the quarter, compared to analysts' expectations of $22.33 million. Albireo Pharma had a negative trailing twelve-month return on equity of 97.13% and a negative net margin of 228.51%. During the same period in the previous year, the company earned ($1.96) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Albireo Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Chicago Capital LLC (6.58%), Franklin Resources Inc. (4.47%), ArrowMark Colorado Holdings LLC (3.80%), GW&K Investment Management LLC (3.07%), Rice Hall James & Associates LLC (2.48%) and Sphera Funds Management LTD. (2.24%). Insiders that own company stock include Jan Mattsson, Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford.
View institutional ownership trends.

Shares of ALBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALBO stock can currently be purchased for approximately $44.15.

Albireo Pharma (NASDAQ:ALBO) has a market capitalization of $913.91 million and generates $40.58 million in revenue each year. The biopharmaceutical company earns $-34,030,000.00 in net income (profit) each year or ($6.72) on an earnings per share basis.

The company employs 130 workers across the globe.

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The official website for the company is www.albireopharma.com. The biopharmaceutical company can be reached via phone at (857) 254-5555, via email at shareholders@biodel.com, or via fax at 203-796-5001.